LBT Innovations Limited (AU:LBT) has released an update.
LBT Innovations Limited, an Australian leader in microbiology automation, showcased its advanced Automated Plate Assessment System (APAS® Independence) at the 2024 AGM. This AI-powered technology, which is the only US FDA-cleared solution for automated culture plate assessment, is being distributed by Thermo Fisher Scientific to clinical labs in the US and Europe. The system is revolutionizing microbiology labs by automating the analysis of culture plates, enhancing efficiency in the pharmaceutical and clinical sectors.
For further insights into AU:LBT stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Deutsche Bank Pounds the Table on Tesla Stock
- ‘Breath of Fresh Air,’ Says Daniel Ives About Rivian Stock
- ‘It’s Not Too Late to Load Up,’ Says Analyst About Nvidia Stock
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
